Opexa Therapeutics recently announced that it has expanded its intellectual property portfolio, which now includes 98 issued and validated patents throughout the world. The company is also seeking to expand its IP protection to cover B-cell mediated diseases as part of the company’s recent launch of its new development program for Neuromyelitis Optica. To date, the Woodlands-based company has been focused on developing personalized immunotherapies for the treatment of autoimmune diseases, such as multiple sclerosis (MS).
As a result of these new efforts, Opexa received a Canadian Notice of Allowance, covering its core T-cell technology platform for developing patient-specific immunotherapies, the “Autologous T-Cell Vaccines Materials and Methods.” The company expects to receive validation of 98 patents from the company’s IP portfolio, which includes in-licensed patents, both in the U.S. and internationally. The group of patents are mainly associated with T-cell mediated autoimmune diseases, such as MS.
“Over the past several years, Opexa has built a significant IP estate around autoimmune diseases that are primarily T-cell mediated diseases, such as multiple sclerosis,” explained the president and chief executive officer of Opexa, Neil K. Warma, who recently presented the company’s novel T-cell immunotherapy for the treatment of MS, Tcelna, at several international conferences and events. “This portfolio now includes almost 100 issued patents in the U.S. and internationally.”
The company has also completed the filing of a U.S. provisional patent application for the expansion in conjunction of its technology designed for the treatment of B-cell mediated autoimmune diseases, such as NMO. In addition, the company also has pending provisional applications that are meant for testing the effectiveness of therapeutic T-cell vaccines and its proprietary screening assay, another resource that the company is presenting in the field of personalized treatment.
“With our recent move into NMO, which is a B-cell mediated disease, we are now pursuing patent coverage that may extend our IP protection across a much broader range of autoimmune disorders, i.e., both T-cell and B-cell disorders, Warma added. “This should enhance our position as a leader in the treatment of autoimmune disorders using personalized immunotherapies.”
In recent news, Opexa had planned a new offering of public shares from their common stock in order to fund the development of their novel therapies, which was terminated three days after its opening due to adverse market conditions, according to the company. Nevertheless, the company remains engaged in the development of what they believe will become a novel, viable, personalized treatment for MS with Tcelna, using Opexa’s proprietary method for the production of a patient-specific T-cell immunotherapy, ImmPath.